$29.50 $0.63 (2.2%)

08:00 PM EDT on 07/02/20

MacroGenics (NASDAQ:MGNX)

CAPS Rating: 2 out of 5

Current Price $29.50 Mkt Cap $1.4B
Open $0.00 P/E Ratio 0.00
Prev. Close $29.50 Div. (Yield) $0.00 (0.0%)
Daily Range $0.00 - $0.00 Volume 1,021,628
52-Wk Range $4.04 - $30.58 Avg. Daily Vol. 4,596,300

Caps

How do you think NASDAQ:MGNX will perform against the market?

Add Stock to CAPS Watchlist

All Players

44 Outperform
5 Underperform
 

All-Star Players

10 Outperform
3 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:MGNX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.10)
Submitted July 08, 2014

MacroGenics seems to be a little more substantial than the other 2013 biopharma IPO's I've recently been catching up on. The company matured their platforms and advanced their pipeline for thirteen years before going public, with the result that the… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:MGNX VS S&P 500 (SPY)

Fools bullish on NASDAQ:MGNX are also bullish on:

Fools bearish on NASDAQ:MGNX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about MGNX.

Recs

0
Member Avatar Bigsef77 (69.45) Submitted: 2/6/2019 10:23:11 AM : Outperform Start Price: $17.63 NASDAQ:MGNX Score: +42.60

MacroGenics stock up 110% after announcing positive Phase 3 trial results

Published: Feb 6, 2019 8:57 a.m. ET

By
Sarah
Toy
Reporter

Shares of biotech MacroGenics Inc. MGNX, +143.02% shot up 110% in premarket trade Wednesday after the company announced that the Phase 3 trial of potential breast cancer treatment margetuximab met its primary endpoint. Margetuximab is the company's monoclonal antibody aimed at treating later-stage breast cancer patients who test positive for a protein called human epidermal growth factor receptor 2, or HER-2. A gene mutation that makes an excess of the HER-2 protein is present in about 15% of primary invasive breast cancers, according to UpToDate, an evidence-based medical resource used by clinicians. This particular trial showed longer progression-free survival in patients treated with a combination of margetuximab and chemotherapy compared to those on trastuzumab (brand name Herceptin) and chemotherapy, a standard-of-care treatment. The company also said approximately 85% of patients in the study were carriers of the CD16A 158F allele, a gene variation has been associated with a reduced clinical response to Herceptin and other antibodies. MacroGenics said it plans to submit a biologics license application to the U.S. Food and Drug Administration in the second half of 2019. Shares of MacroGenics have fallen 13% in the year to date, while the S&P 500 SPX, -0.42% has gained 9.2%.

Recs

0
Member Avatar ice23bear (57.16) Submitted: 1/13/2017 12:36:14 AM : Outperform Start Price: $19.86 NASDAQ:MGNX Score: +11.01

Big pipeline

Recs

0
Member Avatar TTime0917 (< 20) Submitted: 7/23/2014 6:46:23 PM : Outperform Start Price: $22.25 NASDAQ:MGNX Score: -24.24

I'm in on this one.

Leaderboard

Find the members with the highest scoring picks in MGNX.

Score Leader

Playa14

Playa14 (< 20) Score: +232.22

The Score Leader is the player with the highest score across all their picks in MGNX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Playa14 < 20 11/12/2019 Outperform 5Y $8.23 +258.44% +1.01% +257.43 0 Comment
naylorj 74.86 5/7/2020 Outperform 1Y $9.00 +227.78% +8.30% +219.47 0 Comment
sublimeinvestor 34.15 5/30/2019 Outperform 5Y $17.54 +68.19% +11.66% +56.53 0 Comment
Plasmidologist 43.66 5/30/2019 Outperform 5Y $17.54 +68.19% +11.66% +56.53 0 Comment
Bigsef77 69.45 9/19/2017 2/6/2019 Outperform 5Y $17.63 +67.33% +24.73% +42.60 2 Comments
beecha < 20 9/19/2017 Outperform 5Y $17.69 +66.76% +24.72% +42.04 0 Comment
portefeuille3 97.85 12/27/2017 Outperform 5Y $19.35 +52.45% +16.58% +35.87 0 Comment
TheTork 64.74 6/17/2020 Outperform 3W $25.19 +17.11% -0.54% +17.65 0 Comment
ice23bear 57.16 1/13/2017 Outperform 5Y $19.86 +48.54% +37.52% +11.01 1 Comment
TMFGBudwell 79.29 2/6/2019 Outperform 5Y $25.00 +18.00% +14.37% +3.63 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for MGNX.